The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Guidelines for the first-line treatment of restless legs syndrome/Willis–Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation
Open accessAbstract
A Task Force was established by the International Restless Legs Syndrome Study Group (IRLSSG) in conjunction with the European Restless Legs Syndrome Study Group (EURLSSG) and the RLS Foundation (RLS-F) to develop evidence-based and consensus-based recommendations for the prevention and treatment of long-term pharmacologic treatment of dopaminergic-induced augmentation in restless legs syndrome/Willis-Ekbom disease (RLS/WED). The Task Force made the following prevention and treatment recommendations: As a means to prevent augmentation, medications such as α2δ ligands may be considered for initial RLS/WED treatment; these drugs are effective and have little risk of augmentation. Alternatively, if dopaminergic drugs are elected as initial treatment, then the daily dose should be as low as possible and not exceed that recommended for RLS/WED treatment. However, the physician should be aware that even low dose dopaminergics can cause augmentation. Patients with low iron stores should be given appropriate iron supplementation. Daily treatment by either medication should start only when symptoms have a significant impact on quality of life in terms of frequency and severity; intermittent treatment might be considered in intermediate cases. Treatment of existing augmentation should be initiated, where possible, with the elimination/correction of extrinsic exacerbating factors (iron levels, antidepressants, antihistamines, etc.). In cases of mild augmentation, dopamine agonist therapy can be continued by dividing or advancing the dose, or increasing the dose if there are breakthrough night-time symptoms. Alternatively, the patient can be switched to an α2δ ligand or rotigotine. For severe augmentation the patient can be switched either to an α2δ ligand or rotigotine, noting that rotigotine may also produce augmentation at higher doses with long-term use. In more severe cases of augmentation an opioid may be considered, bypassing α2δ ligands and rotigotine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology
Allen, R. P., Picchietti, D., Hening, W. A., Trenkwalder, C., Walters, A. S., & Montplaisi, J. (2003) · Sleep Medicine · doi:10.1016/s1389-9457(03)00010-8 · Cited by 2,900
Self-citationAugmentation of the Restless Legs Syndrome With Carbidopa/Levodopa
Allen, R. P., & Earley, C. J. (1996) · Sleep · doi:10.1093/sleep/19.3.205 · Cited by 451
Self-citationA questionnaire study of 138 patients with restless legs syndrome: The `Night-Walkers' survey
Walters, A. S., Hickey, K., Maltzman, J., Verrico, T., Joseph, D., Hening, W., Wilson, V., & Chokroverty, S. (1996) · Neurology · doi:10.1212/wnl.46.1.92 · Cited by 319
Garcia-Borreguero, D., Kohnen, R., Silber, M. H., Winkelman, J. W., Earley, C. J., Högl, B., Manconi, M., Montplaisir, J., Inoue, Y., & Allen, R. P. (2013) · Sleep Medicine · doi:10.1016/j.sleep.2013.05.016 · Cited by 291
Self-citationGarcía-Borreguero, D., Allen, R. P., Kohnen, R., Högl, B., Trenkwalder, C., Oertel, W., Hening, W. A., Paulus, W., Rye, D., Walters, A., et al. (2007) · Sleep Medicine · doi:10.1016/j.sleep.2007.03.022 · Cited by 285
Self-citationComparison of Pregabalin with Pramipexole for Restless Legs Syndrome
Allen, R. P., Chen, C., Garcia-Borreguero, D., Polo, O., DuBrava, S., Miceli, J., Knapp, L., & Winkelman, J. W. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1303646 · Cited by 241
Self-citationTrenkwalder, C., Beneš, H., Grote, L., García-Borreguero, D., Högl, B., Hopp, M., Bosse, B., Oksche, A., Reimer, K., Winkelmann, J., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70239-4 · Cited by 228
Self-citationAugmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS)
Winkelman, J. W., & Johnston, L. (2004) · Sleep Medicine · doi:10.1016/j.sleep.2003.07.005 · Cited by 217
Self-citationTrenkwalder, C., Beneš, H., Poewe, W., Oertel, W. H., Garcia-Borreguero, D., de Weerd, A. W., Ferini-Strambi, L., Montagna, P., Odin, P., Stiasny-Kolster, K., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70112-1 · Cited by 202
Self-citationSilver, N., Allen, R. P., Senerth, J., & Earley, C. J. (2011) · Sleep Medicine · doi:10.1016/j.sleep.2010.11.002 · Cited by 197
Self-citation
Research works printed but not linked: 7
- Mitterling, 2014, Is there a polysomnographic signature of augmentation in restless legs syndrome?, Sleep Med, 15, 1231, 10.1016/j.sleep.2014.05.023 · doi:10.1016/j.sleep.2014.05.023
- Garcia-Borreguero, 2008, Augmentation in the therapy of restless legs syndrome with transdermal rotigotine: a retrospective systematic analysis of two large double-blind 6-month trials, Eur J Neurol, 15, 110
- Benes, 2009, Augmentation in long-term therapy of the restless legs syndrome with transdermal rotigotine – a retrospective systematic analysis of two large open-label 1-year trials, Mov Disord, 24, S438
- Garcia-Borreguero, 2012, Long-term efficacy and augmentation assessment of a dopamine agonist (pramipexole) compared with an alpha-2-delta ligand (pregabalin) in restless legs syndrome: results of a randomized, double-blinded, placebo-controlled trial, Neurology, 78, P01.
- Godau, 2011, Rotigotine in the long-term treatment of severe RLS with Augmentation: a series of 28 cases, Sleep Disord, 2011, 468952, 10.1155/2011/468952 · doi:10.1155/2011/468952
- Miranda, 2013, [Transdermal Rotigotine in the treatment of restless legs patients who develop augmentation of symptoms], Rev Med Chil, 141, 407
- Kurlan, 2013, Augmentation in restless legs syndrome: poor response to sudden withdrawal of dopaminergic therapy, J Park RLS, 3
Cited by
The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023
Riemann, D., Espie, C. A., Altena, E., Arnardottir, E. S., Baglioni, C., Bassetti, C. L. A., Bastien, C., Berzina, N., Bjorvatn, B., Dikeos, D., et al. (2023) · Journal of Sleep Research · doi:10.1111/jsr.14035 · Cited by 834
“…other ” sleep disorder — this information should also directly inform the therapeutic process, meaning that in many cases the insomnia and the “ other ” sleep disorder will be treated simultaneously according to suggested guidelines/articles (Garcia-Borreguero et al., 2016; Sweetman et al., 2023).”
BackgroundAllen, R. P., Picchietti, D. L., Auerbach, M., Cho, Y. W., Connor, J. R., Earley, C. J., Garcia-Borreguero, D., Kotagal, S., Manconi, M., Ondo, W., et al. (2018) · Sleep Medicine · doi:10.1016/j.sleep.2017.11.1126 · Cited by 349
Self-citationOverview of sleep management during COVID-19.
Becker, P. M. (2022) · Sleep Medicine · doi:10.1016/j.sleep.2021.04.024 · Cited by 51
“Intrinsic circadian rhythm sleep-wake disorders [58], sleep-related movement disorders [59], nightmares [60], autism spectrum disorders [61], and use of opioids during sleep [62] have established practice guidelines as well.”
Background
Metadata
- Authors
- Garcia-Borreguero, D., Silber, M. H., Winkelman, J. W., Högl, B., Bainbridge, J., Buchfuhrer, M., Hadjigeorgiou, G., Inoue, Y., Manconi, M., Oertel, W., Ondo, W., Winkelmann, J., & Allen, R. P.
- Venue
- Sleep Medicine
- Publisher
- Elsevier BV
- Published
- 2016-05
- Volume
- 21
- Pages
- 1-11
- ISSN
- 1389-9457 (ISSN-L)
- OpenAlex
- W2337607729
- Cited by
- 342
- References
- 45
- FWCI
- 29.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Guidelines for the first-line treatment of restless legs syndrome/Willis–Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. https://app.cochat.ai/papers/10.1016/j.sleep.2016.01.017
- The paper
- Garcia-Borreguero, D., Silber, M. H., Winkelman, J. W., Högl, B., Bainbridge, J., Buchfuhrer, M., Hadjigeorgiou, G., Inoue, Y., Manconi, M., Oertel, W., Ondo, W., Winkelmann, J., & Allen, R. P. (2016). Guidelines for the first-line treatment of restless legs syndrome/Willis–Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Medicine. https://doi.org/10.1016/j.sleep.2016.01.017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.